Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mitsui DM Sugar Holdings is a prominent Japanese corporation specializing in sugar refining and the development of functional life science ingredients. Formed by the merger of Mitsui Sugar and Dai-Nippon Meiji Sugar, the company leverages advanced enzymatic technologies to produce unique carbohydrates such as Palatinose and Palatinit. These products are widely utilized in the pharmaceutical and healthcare industries as excipients and clinical nutrition components due to their low-glycemic and slow-release energy properties. Through its subsidiary Nutri Co., the company also provides specialized nutritional products for medical and nursing care settings. Mitsui DM Sugar Holdings maintains a strong focus on health and wellness, contributing to the management of metabolic conditions like diabetes and obesity.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Mitsui Sugar.